Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A New Topical Eye Drop Containing LyeTxI-b, A Synthetic Peptide Designed from A Lycosa erithrognata Venom Toxin, Was Effective to Treat Resistant Bacterial Keratitis

Full text
Author(s):
Show less -
da Silva, Carolina Nunes [1] ; da Silva, Flavia Rodrigues [2] ; Nunes Dourado, Lays Fernanda [1] ; Mendes dos Reis, Pablo Victor [3] ; Silva, Rummenigge Oliveira [1] ; da Costa, Bruna Lopes [1] ; Nunes, Paula Santos [2] ; Amaral, Flavio Almeida [3] ; dos Santos, Vera Lucia [4] ; de Lima, Maria Elena [5] ; Cunha Junior, Armando da Silva [1]
Total Authors: 11
Affiliation:
[1] Univ Fed Minas Gerais, Fac Farm, BR-31270901 Belo Horizonte, MG - Brazil
[2] Univ Fed Sergipe, PPGCAS, BR-49400000 Lagarto, SE - Brazil
[3] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG - Brazil
[4] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG - Brazil
[5] Grp Santa Casa Belo Horizonte, Programa Posgrad Ciencias Saude Biomed & Med, Ensino & Pesquisa Santa Casa Belo Horizonte, BR-30150250 Belo Horizonte, MG - Brazil
Total Affiliations: 5
Document type: Journal article
Source: TOXINS; v. 11, n. 4 APR 2019.
Web of Science Citations: 0
Abstract

Bacterial keratitis is an ocular infection that can lead to severe visual disability. Staphylococcus aureus is a major pathogen of the eye. We recently demonstrated the strong antimicrobial activity of LyeTxI-b, a synthetic peptide derived from a Lycosa erithrognatha toxin. Herein, we evaluated a topical formulation (eye drops) containing LyeTxI-b to treat resistant bacterial keratitis. Keratitis was induced with intrastromal injection of 4 x 10(5) cells (4 mu L) in New Zealand female white rabbits. Minimum inhibitory concentration (MIC) and biofilm viability were determined. LyeTxI-b ocular toxicity was evaluated through chorioallantoic membrane and Draize tests. One drop of the formulation (LyeTxI-b 28.9 mu mol/L +0.5% CMC in 0.9% NaCl) was instilled into each eye four times a day, for a week. Slit-lamp biomicroscopy analysis, corneal histopathological studies and cellular infiltrate quantification through myeloperoxidase (MPO) and N-acetylglucosaminidase (NAG) detection were performed. LyeTxI-b was very effective in the treatment of keratitis, with no signs of ocular toxicity. Planktonic bacteria MIC was 3.6 mu mol/L and LyeTxI-b treatment reduced biofilm viability in 90%. LyeTxI-b eliminated bacteria and reduced inflammatory cellular activity in the eyes. Healthy and treated animals showed similar NAG and MPO levels. LyeTxI-b is a potent new drug to treat resistant bacterial keratitis, showing effective antimicrobial and anti-inflammatory activity. (AU)

FAPESP's process: 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach
Grantee:Maria Vitória Lopes Badra Bentley
Support Opportunities: Research Projects - Thematic Grants